Improvement of SARS-CoV-2 symptoms following Guselkumab injection in a psoriatic patient.
作者信息
Benhadou F, Del Marmol V
机构信息
Dermatology Department, Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium.
出版信息
J Eur Acad Dermatol Venereol. 2020 Aug;34(8):e363-e364. doi: 10.1111/jdv.16590. Epub 2020 Jun 4.
Abstract
摘要
相似文献
1
Improvement of SARS-CoV-2 symptoms following Guselkumab injection in a psoriatic patient.一名银屑病患者注射古塞库单抗后新冠病毒症状改善。
J Eur Acad Dermatol Venereol. 2020 Aug;34(8):e363-e364. doi: 10.1111/jdv.16590. Epub 2020 Jun 4.
2
SARS-CoV-2 infection in a psoriatic patient treated with IL-17 inhibitor.一名接受白细胞介素-17抑制剂治疗的银屑病患者感染了新型冠状病毒。
J Eur Acad Dermatol Venereol. 2020 Aug;34(8):e357-e358. doi: 10.1111/jdv.16571. Epub 2020 Jun 8.
3
SARS-CoV-2 asymptomatic infection in a patient under treatment with dupilumab.正在接受度普利尤单抗治疗的患者出现新型冠状病毒2型无症状感染。
J Eur Acad Dermatol Venereol. 2020 Aug;34(8):e368. doi: 10.1111/jdv.16619. Epub 2020 Jun 8.
4
'Toxic erythema' and eosinophilia associated with tocilizumab therapy in a COVID-19 patient.一名新冠患者中与托珠单抗治疗相关的“中毒性红斑”和嗜酸性粒细胞增多症
J Eur Acad Dermatol Venereol. 2020 Aug;34(8):e368-e370. doi: 10.1111/jdv.16620. Epub 2020 Jun 8.
5
COVID-19 pulmonary infection in erythrodermic psoriatic patient with oligodendroglioma: safety and compatibility of apremilast with critical intensive care management.患有少突胶质细胞瘤的红皮病型银屑病患者的COVID-19肺部感染：阿普米司特与重症监护管理的安全性和兼容性
J Eur Acad Dermatol Venereol. 2020 Aug;34(8):e376-e378. doi: 10.1111/jdv.16625. Epub 2020 Jun 4.
6
Safety of dupilumab in severe atopic dermatitis and infection of Covid-19: two case reports.度普利尤单抗在重度特应性皮炎中的安全性及新型冠状病毒肺炎感染：两例病例报告
J Eur Acad Dermatol Venereol. 2020 Jul;34(7):e303-e304. doi: 10.1111/jdv.16527. Epub 2020 Jun 8.
7
Complicated coronavirus disease 2019 (COVID-19) in a psoriatic patient treated with ixekizumab.一名使用司库奇尤单抗治疗的银屑病患者发生的复杂型2019冠状病毒病（COVID-19）
Int J Dermatol. 2020 Aug;59(8):e267-e268. doi: 10.1111/ijd.15008. Epub 2020 Jun 18.
8
Evolution of COVID-19 infection in four psoriatic patients treated with biological drugs.4例接受生物制剂治疗的银屑病患者的新型冠状病毒肺炎感染演变情况
J Eur Acad Dermatol Venereol. 2020 Aug;34(8):e360-e361. doi: 10.1111/jdv.16587. Epub 2020 Jun 8.
9
Status of a real-life cohort of patients with moderate-to-severe plaque psoriasis treated with secukinumab and considerations on the use of biological agents in the Covid-19 era.中重度斑块状银屑病患者真实世界队列的现状，以及在新冠疫情时代使用生物制剂的相关考虑。
Expert Opin Biol Ther. 2020 Aug;20(8):829-830. doi: 10.1080/14712598.2020.1779217. Epub 2020 Jun 16.
10
Tocilizumab administration in a refractory case of COVID-19.托珠单抗在一例难治性新型冠状病毒肺炎病例中的应用
Int J Antimicrob Agents. 2020 Aug;56(2):106043. doi: 10.1016/j.ijantimicag.2020.106043. Epub 2020 Jun 2.
引用本文的文献
1
Weathering the Storm: How Age and Biologics Influence the COVID-19 Cytokine Surge.经受住风暴：年龄和生物制剂如何影响COVID-19细胞因子风暴
Pathogens. 2025 Apr 3;14(4):346. doi: 10.3390/pathogens14040346.
2
Management of Psoriasis Patients with Serious Infectious Diseases.严重感染性疾病银屑病患者的管理。
Adv Ther. 2024 Jun;41(6):2099-2111. doi: 10.1007/s12325-024-02873-2. Epub 2024 May 6.
3
A systematic review and meta-analysis of investigating the mutual impact of COVID-19 and psoriasis: Focusing on COVID-19 course in psoriasis and the opinion on biologics in this setting.一项关于探究2019冠状病毒病（COVID-19）与银屑病相互影响的系统评价和荟萃分析：聚焦银屑病患者的COVID-19病程及在此背景下对生物制剂的看法。
Immun Inflamm Dis. 2023 Nov;11(11):e1063. doi: 10.1002/iid3.1063.
4
The Impact of Immune-Modulating Treatments for Dermatological Diseases on the Risk of Infection with SARS-CoV-2 and Outcomes Associated with COVID-19 Illness.皮肤科疾病免疫调节治疗对感染严重急性呼吸综合征冠状病毒2（SARS-CoV-2）风险及与冠状病毒病（COVID-19）相关结局的影响
Curr Dermatol Rep. 2023;12(2):45-55. doi: 10.1007/s13671-023-00385-w. Epub 2023 Apr 3.
5
An Erythrodermic Psoriasis Flare-Up With Staphylococcus Bacteremia Secondary to COVID-19 Infection: A Case Report.1例继发于新型冠状病毒肺炎感染的红皮病型银屑病发作伴葡萄球菌菌血症：病例报告
Cureus. 2023 Mar 20;15(3):e36418. doi: 10.7759/cureus.36418. eCollection 2023 Mar.
6
Cytokines and microRNAs in SARS-CoV-2: What do we know?严重急性呼吸综合征冠状病毒2中的细胞因子和微小RNA：我们了解什么？
Mol Ther Nucleic Acids. 2022 Sep 13;29:219-242. doi: 10.1016/j.omtn.2022.06.017. Epub 2022 Jun 25.
7
Treatment of Moderate to Severe Psoriasis during the COVID-19 Pandemic: Lessons Learned and Opportunities.2019年冠状病毒病大流行期间中重度银屑病的治疗：经验教训与机遇
J Clin Med. 2022 Apr 26;11(9):2422. doi: 10.3390/jcm11092422.
8
Erythrodermic flare-up of psoriasis with COVID-19 infection: A report of two cases and a comprehensive review of literature focusing on the mutual effect of psoriasis and COVID-19 on each other along with the special challenges of the pandemic.银屑病红皮病型发作合并新型冠状病毒肺炎感染：两例报告及文献综述，重点关注银屑病与新型冠状病毒肺炎的相互影响以及疫情带来的特殊挑战
Clin Case Rep. 2022 Apr 20;10(4):e05722. doi: 10.1002/ccr3.5722. eCollection 2022 Apr.
9
A Peek into Pandora's Box: COVID-19 and Neurodegeneration.窥探潘多拉魔盒：新冠病毒与神经退行性变
Brain Sci. 2022 Jan 30;12(2):190. doi: 10.3390/brainsci12020190.
10
Management of Psoriasis During the Coronavirus Disease 2019 Pandemic.2019年冠状病毒病大流行期间银屑病的管理
J Clin Aesthet Dermatol. 2021 Sep;14(9):41-44.
本文引用的文献
1
COVID-19: risk for cytokine targeting in chronic inflammatory diseases?COVID-19：慢性炎症性疾病中细胞因子靶向治疗的风险？
Nat Rev Immunol. 2020 May;20(5):271-272. doi: 10.1038/s41577-020-0312-7.
2
SARS-CoV-2 infection in a psoriatic patient treated with IL-23 inhibitor.一名接受白细胞介素-23抑制剂治疗的银屑病患者感染了新型冠状病毒。
J Eur Acad Dermatol Venereol. 2020 Jun;34(6):e254-e255. doi: 10.1111/jdv.16468. Epub 2020 Jun 10.
3
Reply to: "COVID-19, syphilis, and biologic therapies for psoriasis and psoriatic arthritis: A word of caution".回复：“2019冠状病毒病、梅毒与银屑病和银屑病关节炎的生物疗法：一则警示”
J Am Acad Dermatol. 2020 Jun;82(6):e215. doi: 10.1016/j.jaad.2020.03.103. Epub 2020 Apr 10.
4
In the eye of the COVID-19 cytokine storm.在新冠病毒细胞因子风暴的视角下。
Nat Rev Immunol. 2020 May;20(5):277. doi: 10.1038/s41577-020-0305-6.
5
COVID-19: consider cytokine storm syndromes and immunosuppression.2019冠状病毒病：考虑细胞因子风暴综合征和免疫抑制。
Lancet. 2020 Mar 28;395(10229):1033-1034. doi: 10.1016/S0140-6736(20)30628-0. Epub 2020 Mar 16.
6
Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER-3).依奇珠单抗治疗中重度斑块状银屑病的疗效和安全性：一项随机、对照 3 期临床试验（UNCOVER-3）的 108 周结果。
J Am Acad Dermatol. 2017 Nov;77(5):855-862. doi: 10.1016/j.jaad.2017.06.153. Epub 2017 Sep 13.
7
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. Guselkumab，一种抗白细胞介素-23 单克隆抗体，与阿达木单抗相比，用于中重度银屑病患者的连续治疗：来自 III 期、双盲、安慰剂和活性对照 VOYAGE 1 试验的结果。
J Am Acad Dermatol. 2017 Mar;76(3):405-417. doi: 10.1016/j.jaad.2016.11.041. Epub 2017 Jan 2.
Zotero 插件